MICHAEL JOHNSON: Open Payments
NPI 1326132408 · LAWRENCEVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,868 in 117 payments from 26 companies in 2025. Trend: 2023 $796 · 2024 $1,634 · 2025 $1,868
Food & beverage: $1,868
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $427 |
| Vanda Pharmaceuticals Inc. | 9 | $217 |
| Novo Nordisk Inc | 15 | $211 |
| Otsuka America Pharmaceutical, Inc. | 10 | $189 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| AstraZeneca Pharmaceuticals LP | 4 | $73 |
| Lilly USA, LLC | 3 | $64 |
| Neurocrine BioSciences, Inc. | 3 | $53 |
| Lundbeck LLC | 2 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
Products named: VRAYLAR, REXULTI, HETLIOZ, Ozempic, Auvelity, UBRELVY, INGREZZA, ZORYVE.
Industry payments across GA — which companies pay providers there.
